Perspective Therapeutics Advances Two Radiopharmaceutical Trials with New Patient Cohorts — Perspective Therapeutics, Inc.

Event summary

First patients dosed in new cohorts of two Phase 1/2a studies for neuroendocrine tumors and solid tumors.
Fourth cohort of [212Pb]VMT-α-NET trial explores front-loading dosing regimen for optimized response kinetics.
Third cohort of [212Pb]PSV359 trial cleared to open after safety review of Cohort 2 data.
Interim analysis of [212Pb]VMT-α-NET presented at AACR 2026; additional data pending for 2026 conferences.

The big picture

Perspective Therapeutics is advancing its radiopharmaceutical pipeline with two key trials targeting neuroendocrine tumors and solid tumors. The company's theranostic approach, combining imaging and therapy, aims to enhance treatment personalization and efficacy. The progress in these trials is critical for validating the company's proprietary 212Pb-based technology and its potential to address unmet needs in oncology.

What we're watching

Dosing Optimization: Whether front-loading in [212Pb]VMT-α-NET improves response rate and tolerability.
Safety and Efficacy: The pace at which [212Pb]PSV359 demonstrates anti-tumor activity in solid tumors.
Regulatory Pathway: How interim and additional data influence the Phase 2 dose recommendation for PSV359.